SARS-CoV-2 Mpro-IN-41

SARS-CoV-2 Mpro-IN-41 (Compound 7e) is an orally active inhibitor of COX-2 and SARS-CoV-2 M pro (IC50 values are 9.66 μM and 13.24 μM, respectively) . SARS-CoV-2 Mpro-IN-41 also has a certain inhibitory activity against COX-1 (IC50: 46.11 μM) . SARS-CoV-2 Mpro-IN-41 can significantly inhibit the expression of inflammatory-related cytokines (such as TNF-α, IL-6, IL-1β) and exert anti-inflammatory effects. SARS-CoV-2 Mpro-IN-41 exerts anti-inflammatory and antiviral effects by selectively inhibiting COX-2 and SARS-CoV-2 M pro. SARS-CoV-2 Mpro-IN-41 can be used for anti-inflammatory and anti-coronavirus research[1].

Product Specifications

UNSPSC

12352005

Target

COX; SARS-CoV

Related Pathways

Anti-infection; Immunology/Inflammation

Field of Research

Infection; Inflammation/Immunology

Smiles

O=C(C(C1=NN(C2=CC=C(S(=O)(C)=O)C=C2)C(C3=CC=C(Cl)C=C3)=C1)=C(C)N4C)N4C5=CC=CC=C5

Molecular Formula

C27H23ClN4O3S

Molecular Weight

519.01

References & Citations

[1]Abdelall EKA, et al. Synthesis of new selective agents with dual anti-inflammatory and SARS-CoV-2 Mpro inhibitory activity: Antipyrine-celecoxib hybrid analogues; COX-2, COVID-19 cytokine storm and replication inhibitory activities. Bioorg Chem. 2025 Jun 15;160:108429.